Articles tagged "Post-transplant lymphoproliferative disorder (PTLD)"

2020 American Transplant Congress
Long-Term Safety in Epstein-Barr Virus (EBV)-Seropositive Kidney-Only Transplant Recipients Treated with Belatacept (BELA) in Clinical Practice: Final Study Results from the ENLiST Registry
C. Larsen¹, F. Vincenti², T. Kou³, C. Shadur⁴, B. Bresnahan⁵, S. Jordan⁶, E. S. Woodle⁷, N. Goes⁸, J. Vella⁹, D. Wojciechowski¹⁰, M. Polinsky³, A. Gomez-Caminero³
¹Emory University Transplant Center, Atlanta, GA, ²UCSF Transplant Center, San Francisco, CA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Iowa Kidney Physicians, Des Moines, IA, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Cedars-Sinai Medical Center, Los Angeles, CA, ⁷University of Cincinnati, Cincinnati, OH, ⁸Kaiser Permanente, San Francisco, CA, ⁹Maine Nephrology Associates, PA, Portland, ME, ¹⁰University Hospital Kidney and Liver Transplant Clinic, Dallas, TX
*Purpose: BELA, a selective T-cell costimulation blocker, is approved for the prophylaxis of organ rejection in EBV-seropositive adult kidney transplant recipients. In phase 3 BENEFIT…
2020 American Transplant Congress
Lifetime Survival Estimates Following Solid Organ Transplantation in the United States
C. Graham¹, M. Skeans², Y. Ahn², C. Watson³, A. Barlev⁴
¹RTI Health Solutions, Research Triangle Park, NC, ²Chronic Disease Research Group, Minneapolis, MN, ³Atara Biotherapeutics, South San Francisco, CA, ⁴Atara Biotherapeutics, Thousand Oaks, CA
*Purpose: The Scientific Registry of Transplant Recipients (SRTR) contains detailed patient and graft survival data for all solid organ transplants (SOT) in the United States…
2020 American Transplant Congress
Evaluation of Infectious and Malignant Complications in Elderly Renal Transplant Recipients Receiving Alemtuzumab Compared to Basiliximab
K. Lang¹, J. Shulte¹, K. Cunningham¹, C. D'Agostino¹, M. Kapugi¹, C. Kane¹, A. Novak¹, J. Leventhal²
¹Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Division of Transplant Surgery, Northwestern Memorial Hospital, Chicago, IL
*Purpose: The choice of induction immunosuppression can affect several outcomes after kidney transplant (KTx), especially for elderly recipients. For this population, there is limited data…
2020 American Transplant Congress
Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte Precursors (EBV-CTLp) after Tab-cel Correlates with Response & Survival in Rituximab Relapsing or Refractory Ebv⁺ Posttransplant Lymphoproliferative Disease (PTLD)
R. Shen¹, N. Guzman-Becerra¹, Y. Sun¹, F. Forozan¹, S. Prockop², E. Doubrovina², R. O'Reilly², X. Li¹, M. Hiremath³, L. Gamelin¹, W. Navarro¹, B. Aftab¹
¹Atara Biotherapeutics, Thousand Oaks, CA, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Atara Biotherapeutics, South San Francisco, CA
*Purpose: EBV+ PTLD is often a fatal disease. Tab-cel is an investigational off-the-shelf, allogeneic T-cell immunotherapy specific for EBV antigens. Functional in vivo expansion approximated…
2020 American Transplant Congress
Transplant Monitoring and PTLD Detection with B Cell Receptor Repertoire Analysis in a Large Prospective Pediatric Cohort
K. Jackson¹, O. Martinez², S. Krams², M. Robien³, M. Lapasaran², B. Armstrong⁴, C. Twist⁵, K. Weinberg⁶, D. Gratzinger¹, B. Tam¹, M. Sever⁴, M. Brown³, D. Bernstein⁶, C. Esquivel², S. D. Boyd¹
¹Department of Pathology, Stanford Univ School of Med, Stanford, CA, ²Department of Surgery/Division of Abdominal Transplantation, Stanford Univ School of Med, Stanford, CA, ³NIAID, NIH, Bethesda, MD, ⁴Rho, Chapel Hill, NC, ⁵Roswell Park, Buffalo, NY, ⁶Department of Pediatrics, Stanford Univ School of Med, Stanford, CA
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOT-C)-06 is a…
2020 American Transplant Congress
Outcomes of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders: An Analysis of the UNOS/OPTN Database (1998 to 2019)
W. Cheungpasitporn¹, C. Thongprayoon², C. C. Jadlowiec³, W. J. Chon⁴, L. S. Cummings⁴, S. R. Katari⁴, N. Leeaphorn⁴
¹Nephrology, University of Mississippi Medical Center, Jackson, MS, ²Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ³Transplant Surgery, Mayo Clinic, Phoenix, AZ, ⁴Renal Transplant Program, University of Missouri-Kansas City School of Medicine/Saint Luke's Health System, Kansas City, MO
*Purpose: Post-transplant lymphoproliferative disease (PTLD) is a serious, potentially fatal complication after kidney transplantation. Existing literature on outcomes of kidney retransplantation in patients with prior…
2020 American Transplant Congress
Patterns of Belatacept Use and Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) in US Kidney Transplant Recipients – Analysis of Organ Procurement and Transplantation Network (OPTN) Database
W. S. Cherikh¹, T. Kou², J. Foutz¹, A. Gomez-Caminero²
¹United Network for Organ Sharing (UNOS), Richmond, VA, ²Bristol-Myers Squibb, Princeton, NJ
*Purpose: Belatacept, a selective T-cell costimulation blocker, was approved in 2011 for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients. PTLD…
2020 American Transplant Congress
Long-Term Outcomes of Patients with Epstein-barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in an Expanded Access Program Study
S. Prockop¹, R. Reshaf², D. Tsai³, N. Bunin⁴, R. Abu-Arja⁵, K. Mahadeo⁶, W. Weng⁷, K. Van Besien⁸, D. Loeb⁹, S. Dwivedy Nasta¹⁰, E. Nemecek¹¹, M. Hiremath¹², S. Yue¹², Y. Sun¹², W. Navarro¹², S. Nikiforow¹³
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Loxo Oncology, Stamford, CT, ⁴The Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶MD Anderson Cancer Center, Houston, TX, ⁷Stanford University School of Medicine, California, CA, ⁸Weill Cornell Medical College, New York, NY, ⁹Children's Hospital at Montefiore, Bronx, NY, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Oregon Health & Science University, Portland, OR, ¹²Atara Biotherapeutics, New York, NY, ¹³Dana Farber Cancer Institute, Boston, MA
*Purpose: There is a need for effective, well‑tolerated therapies in pts who develop Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ (SOT) or…
2020 American Transplant Congress
Evaluation of Host Immune Responses to Epstein-Barr Virus in Lung Transplant Recipients
L. Zaffiri¹, J. E. Messinger², J. Yi², K. J. Weinhold², G. Ferrari², M. Luftig², S. M. Palmer¹
¹Pulmonary and Critical Care, Duke University, Durham, NC, ²Duke University, Durham, NC
*Purpose: After lung transplantation, Epstein-Barr virus (EBV) is a common opportunistic infection. The significance of EBV viremia following solid organ transplantation (SOT) remains unclear. Host…
2020 American Transplant Congress
Genome-Wide Analysis of Epstein Barr Virus Identifies Variations in the Latency Gene EBNA3C That Are Associated with Post Transplant Lymphoproliferative Disorder
E. Maloney, J. Toh, S. M. Krams, C. O. Esquivel, O. M. Martinez
Stanford University Sch of Med, Stanford, CA
*Purpose: Epstein Barr virus (EBV) is a gamma herpes virus that is associated with a variety of human malignancies including EBV+ B cell lymphomas in…